PDCD1 and head and neck squamous cell carcinoma: Recently, two anti-PD-1 immune checkpoint inhibitors (ICIs), pembrolizumab and nivolumab, have been approved for the treatment of recurrent and metastatic HNSCC [5] for first-line [6] and second-line treatment either as a monotherapy or in combination with platinum-based chemotherapy [7,8].